This “Hepatitis A- Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatitis A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Hepatitis A is a highly contagious, short-term liver infection caused by the hepatitis A virus. People who get hepatitis A may feel sick for a few weeks to several months but usually recover completely and do not have lasting liver damage. In rare cases, hepatitis A can cause liver failure and even death; this is more common in older people and in people with other serious health issues, such as chronic liver disease. The hepatitis A virus is found in the stool and blood of people who are infected. The hepatitis A virus is spread when someone ingests the virus (even in amounts too small to see) through: Person-to-person contact, Hepatitis A can be spread from close, personal contact with an infected person. Eating contaminated food or drink: Contamination of food with the hepatitis A virus can happen at any point: growing, harvesting, processing, handling, and even after cooking. Contamination of food and water happens more often in countries where hepatitis A is common. Although anyone can get hepatitis A, in the United States, certain groups of people are at higher risk for getting infected and for having severe disease if they do get hepatitis A. A single shot of the hepatitis A vaccine can help prevent hepatitis A if given within 2 weeks of exposure. Not everyone with hepatitis A has symptoms. Adults are more likely to have symptoms than children. If symptoms develop, they usually appear 2 to 7 weeks after infection. Symptoms usually last less than 2 months, although some people can be ill for as long as 6 months. If symptoms develop, they can include: Yellow skin or eyes, not wanting to eat, upset stomach, throwing up, stomach pain, fever, dark urine or light- colored stools. Many people, especially children, have no symptoms but can still spread the infection. In addition, a person can transmit the hepatitis A virus to others up to 2 weeks before symptoms appear.
“Hepatitis A- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis A pipeline landscape is provided which includes the disease overview and Hepatitis A treatment guidelines. The assessment part of the report embraces, in depth Hepatitis A commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis A collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Hepatitis A report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Inactivated Hepatitis A Vaccine: Biological E Limited
Biological E Limited is developing an Inactivated Hepatitis A Vaccine. The vaccine is currently in Phase III stage of clinical trial evaluation.
Hepatitis A vaccine inactivated: Indian Immunologicals
Inactivated hepatitis A vaccine is being developed by Indian Immunologicals for prevention of Hepatitis A infection. The vaccine is currently in Phase II/III stage of clinical trial evaluation.
This segment of the report provides insights about the different Hepatitis A drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Hepatitis A. The companies which have their Hepatitis A drug candidates in the most advanced stage, i.e. phase III include, Biological E Limited.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis A therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis A drugs.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Hepatitis A: Understanding
Hepatitis A: Overview
Hepatitis A is a highly contagious, short-term liver infection caused by the hepatitis A virus. People who get hepatitis A may feel sick for a few weeks to several months but usually recover completely and do not have lasting liver damage. In rare cases, hepatitis A can cause liver failure and even death; this is more common in older people and in people with other serious health issues, such as chronic liver disease. The hepatitis A virus is found in the stool and blood of people who are infected. The hepatitis A virus is spread when someone ingests the virus (even in amounts too small to see) through: Person-to-person contact, Hepatitis A can be spread from close, personal contact with an infected person. Eating contaminated food or drink: Contamination of food with the hepatitis A virus can happen at any point: growing, harvesting, processing, handling, and even after cooking. Contamination of food and water happens more often in countries where hepatitis A is common. Although anyone can get hepatitis A, in the United States, certain groups of people are at higher risk for getting infected and for having severe disease if they do get hepatitis A. A single shot of the hepatitis A vaccine can help prevent hepatitis A if given within 2 weeks of exposure. Not everyone with hepatitis A has symptoms. Adults are more likely to have symptoms than children. If symptoms develop, they usually appear 2 to 7 weeks after infection. Symptoms usually last less than 2 months, although some people can be ill for as long as 6 months. If symptoms develop, they can include: Yellow skin or eyes, not wanting to eat, upset stomach, throwing up, stomach pain, fever, dark urine or light- colored stools. Many people, especially children, have no symptoms but can still spread the infection. In addition, a person can transmit the hepatitis A virus to others up to 2 weeks before symptoms appear.
“Hepatitis A- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis A pipeline landscape is provided which includes the disease overview and Hepatitis A treatment guidelines. The assessment part of the report embraces, in depth Hepatitis A commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis A collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis A R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis A.
Hepatitis A Emerging Drugs Chapters
This segment of the Hepatitis A report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatitis A Emerging Drugs
Inactivated Hepatitis A Vaccine: Biological E Limited
Biological E Limited is developing an Inactivated Hepatitis A Vaccine. The vaccine is currently in Phase III stage of clinical trial evaluation.
Hepatitis A vaccine inactivated: Indian Immunologicals
Inactivated hepatitis A vaccine is being developed by Indian Immunologicals for prevention of Hepatitis A infection. The vaccine is currently in Phase II/III stage of clinical trial evaluation.
Hepatitis A: Therapeutic Assessment
This segment of the report provides insights about the different Hepatitis A drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hepatitis A
There are approx. 3+ key companies which are developing the therapies for Hepatitis A. The companies which have their Hepatitis A drug candidates in the most advanced stage, i.e. phase III include, Biological E Limited.
Phases
This report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Hepatitis A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hepatitis A: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis A therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis A drugs.
Hepatitis A Report Insights
- Hepatitis A Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hepatitis A Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hepatitis A drugs?
- How many Hepatitis A drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis A?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatitis A therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hepatitis A and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Indian Immunologicals
- Biological E Limited
- Zydus Lifesciences
Key Products
- Inactivated Hepatitis A Vaccine
- Hepatitis A vaccine inactivated
- HAV 1001
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Hepatitis A: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Hepatitis A – Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Inactivated Hepatitis A Vaccine: Biological E Limited
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II/III)
- Comparative Analysis
HAV 1001: Cadila Healthcare
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Inactive Products
- Comparative Analysis
Hepatitis A Key Companies
Hepatitis A Key Products
Hepatitis A - Unmet Needs
Hepatitis A - Market Drivers and Barriers
Hepatitis A - Future Perspectives and Conclusion
Hepatitis A - Analyst Views
Hepatitis A - Key Companies
Appendix
List of Tables
Table 1 Total Products for Hepatitis A
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Hepatitis A
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Indian Immunologicals
- Biological E Limited
- Zydus Lifesciences
